Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab

Leuk Lymphoma. 2009 Mar;50(3):463-5. doi: 10.1080/10428190802641979.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD34
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Count
  • Cyclophosphamide / administration & dosage*
  • Female
  • Hematopoietic Stem Cell Mobilization / methods*
  • Humans
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Middle Aged
  • Rituximab
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD34
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine